DPP4 and type 2 diabetes mellitus: This preliminary investigation demonstrated that T2D patients with high GV who switched from a DPP-4 inhibitor plus IDeg to IDegLira had an improvement in MAGE and that this improvement would depend on relatively intact beta-cell function, assessed using ΔCPR.